Literature DB >> 1290844

Ten-year prognosis for generalized infantile eczema.

O Linna1, J Kokkonen, P Lahtela, O Tammela.   

Abstract

Forty children treated in our hospital for generalized infantile eczema were re-examined at 11-13 years of age. In 7 (18%) children the eczema had disappeared and in 26 (65%) it had become less severe. Unrelated to dermatological status or gender, allergic rhinitis was diagnosed in 31 (78%) and asthma in 21 (53%) children. Only 8 children continued without either of these two conditions. All 32 children with allergic rhinitis and/or asthma showed at least one positive skin test reaction in a test panel of 11 common inhalant and food allergens compared with only 4 of 8 children without either allergic rhinitis or asthma (p < 0.001). Our results showed an improvement of dermatological status in most children with generalized infantile eczema but there was a high risk of a concomitant respiratory allergy and development of allergic rhinitis or asthma.

Entities:  

Mesh:

Year:  1992        PMID: 1290844     DOI: 10.1111/j.1651-2227.1992.tb12165.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  4 in total

Review 1.  Genome-wide association studies in the genetics of asthma.

Authors:  Saffron A G Willis-Owen; William O Cookson; Miriam F Moffatt
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

Review 2.  Omalizumab : other indications and unanswered questions.

Authors:  Vaishali S Mankad; A Wesley Burks
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

Review 3.  Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  Am J Clin Dermatol       Date:  2022-05-31       Impact factor: 6.233

4.  Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

Authors:  Douglas A Plager; Susan A Henke; Yoshinori Matsuwaki; Arvind Madaan; Diane L Squillace; Ross A Dierkhising; Hirohito Kita
Journal:  Int Arch Allergy Immunol       Date:  2009-01-06       Impact factor: 2.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.